Slide 1: Financial Statements Bulletin January–December 2025 Webcast
Financial Statements Bulletin January–December 2025 Webcast February 13, 2026
Slide 2: Today's speakers
Today’s speakers Sarah van Hellenberg Tuukka Paavola Hubar-Fisher CEO CFO
Slide 3: 2025: Rebuilding for Commercial Growth
2025: Rebuilding for Commercial Growth Key transitions in preparation for the next phase of growth • CEO & CFO transition • 5 Management Team member changes • New U.S. Distributor Operating Model • Go-to-Market strategy and operations adjustments • Organizational performance enhancements • Updated f
Slide 4: 2025 U.S. milestones
2025 U.S. milestones Accelerating Growth through Regulatory Wins, Partnerships, and Execution Regulatory & Market Access Execution & Growth FDA TPT 17 60% KOLs Breakthrough Payment VAC Approvals Q/Q Growth Signed Q4 '25 FDA Breakthrough Device Designation granted for RemeOs 60% Average Q/Q Growth ac
Slide 5: 2025 OUS milestones
2025 OUS milestones Strategic expansion and diversification in key OUS markets Current Footprint & New Partners January 2025: CE mark approval for the RemeOsTM Trauma Screw portfolio Distributor changes completed YE 2025: Joint Operations Ltd appointed in UK & Ireland; Joint Operations GmbH in Germa
Slide 6: Financials 2025
Financials 2025 EUR 1,000 unless otherwise indicated 1–12/2025 1–12/2024 Change, % Net sales 3,522 4,544 -22.5% Sales margin 65.7% 70.9% Financial results reflect absorbing EBITDA -8,476 -4,053 significant changes to leadership and operating model Profit / loss for the period -9,483 -4,614 Cash and
Slide 7: Strategic Priorities & Financial Targets for 2026–2028
Strategic Priorities & Financial Targets for 2026–2028 Demonstrate industry leading innovation, clinical evidence generation, and commercial scale Industry Leading by progressing a strong R&D pipeline and introducing at least one new product or indication Innovation every 12–18 months, reflected by
Slide 8: Recognized Leadership in Driving the Shift to Absorbables
Recognized Leadership in Driving the Shift to Absorbables Bioretec will lead the charge on bioabsorbable implant growth globally https://www.databridgemarketresearc h.c om/reports/global-bioabsorbable-orthopedic-implants-market
Slide 9: Near Term Product Launches: Path to Growth
Near Term Product Launches: Path to Growth Activa Headless RemeOs FT Screw RemeOs DrillPin FDA 510(k) Pending FDA 510(k) Path Trials Enrolling Sizes: 3.5 - 4.5 Length: 20–90 Sizes: 3.5 – 4.0 Length: 24 – 50 Market Disruption mm mm mm mm Self-drilling (No K-wire) 850K Hammertoe TAM: Sizes: 1.9–3.2 mm
Slide 10: Product Pipeline — Estimated Launch Cadence
Product Pipeline — Estimated Launch Cadence Mg alloy Hybrid Each major product launch adds €3–5M annual revenue potential at scale Short-Term Mid-Term Long-Term Re meOs FT Headless 2026 ~$0.7B TAM Differentiated Trauma ~$3.0B TAM Spine P ortfolio ~$3.0B TAM BREA KTHROUG H DEVIC E BREA KTHR OUG H DEV
Slide 11: Market Momentum: Leading Surgeons are Ready for the Absorbable Shift
Market Momentum: Leading Surgeons are Ready for the Absorbable Shift Prof. Dr. Christopher DiGiovanni Dr. Robert Leland FACFAS, do uble Bo ard Ce rtified Foo t an d An kle surgeon , FACFAS, Board Certified Fo ot & An kle Su rgeon “Absorbable fixa tion is p ositioned to become an increasingly importa
Slide 12: Questions & Answers
Questions & Answers Two Absorbable Technologies, One Goal — Healing Beyond Absorption
Slide 13: Pathways to value creation
Pathways to value creation Activa RemeOs Trauma RemeOs Spine Proprietary manufacturing process extends Near term trauma portfolio expe cted in Pre-comm ercial partnership strate gy protection beyond current patent life <18 months SI screw se rving as strategic door opener Clear repeat market demand
Slide 14: $14B+ market potential with strong absorbables CAGR
$14B+ market potential with strong absorbables CAGR Addressable market for full product line-up >$14B… … with strong absorbables outlook (CAGR 10%+) Addressable market, 2024 estimate $14.0B +$10.0B $2.5B Trauma Screw market alone to reach ~$2.5B $3.0B Differentiated Trauma by 2033 $1.4 Titanium (56%
Slide 15: Two Absorbable Technologies, One Goal — Healing Beyond Absorption
Two Absorbable Technologies, One Goal — Healing Beyond Absorption